The news sent the company’s stock to its lowest level since March 2009. NeurogesX hasn’t reported a profit since the company began selling shares in 2007, and the stock has fallen 83 percent in the past year.
Advisors are scheduled to meet with regulators tomorrow, and a final decision is expected by March 7.
Sign up for our FREE Pain E-Weekly for more coverage like this sent to your inbox!
Related Articles on Pain Management:
5 Points on MILD From Dr. John Hong of Gateway Spine & Pain Physicians
Study: Spinal Cord Stimulation Effective for HIV Neuropathy
Pain Center of Arizona Opens New Clinic in Phoenix
